TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04211675
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan 50mg/m2/dose IV daily on Days 1-5
Study: NCT04211675
Drug: Dinutuximab
Normalized name: Dinutuximab
DrugBank: Dinutuximab (DB09077)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dinutuximab 17.5mg/m2/dose IV daily on Days 2-5
Study: NCT04211675
Drug: Sargramostim
Normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sargramostim 250mcg/m2/dose subcutaneous daily on Days 6-12
Study: NCT06260774
Drug: TTX-MC138
Normalized name: TTX-MC138
DrugBank: TTX-MC138 (DB18628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose of TTX-MC138 in the first cohort will be 0.4 mg/kg and will be increased incrementally in subsequent cohorts until maximum tolerated dose (MTD) determination.
Study: NCT06011733
Drug: Bimekizumab
Normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Study participants will receive bimekizumab (dosage regimen 1 and 2) subcutaneously administered at pre-specified time points during the Initial and Maintenance Treatment Periods.
Study: NCT05498220
Drug: Polatuzumab vedotin (PV)
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.8 mg/kg, intravenous, at day 1, in every 21 days
Study: NCT05498220
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m2 intravenous, at day 1 or day 2, in every 21 days
Study: NCT05498220
Drug: Hyaluronidase
Normalized name: Hyaluronidase
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1,400 mg/23,400 units sub-cutaneous, starts at cycle 2, in every 21 days
Study: NCT04331743
Drug: Liposome-entrapped Mitoxantrone Hydrochloride Injection
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT05498220
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1,000 mg/m2 intravenous at day 1 and 8, in every 21 days
Study: NCT05498220
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2, intravenous, at day 1, in every 21 days
Study: NCT05498220
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg intravenous at day 1, Per oral days at days 2-4
Study: NCT05498220
Drug: GCSF
Normalized name: GlycoPEG-GCSF
DrugBank: GlycoPEG-GCSF (DB06022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: granulocyte-colony stimulating factor (GCSF )
Study: NCT06476132
Drug: Belumosudil
Normalized name: BELUMOSUDIL
DrugBank: Belumosudil (DB16703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive Belumosudil 200 mg daily (increased to 200 mg twice daily in participants receiving concurrent strong CYP3A inducers or PPIs) + maintenance IS for a duration of one year from randomization.
Study: NCT06476132
Drug: Placebo for Belumosudil
Normalized name: belumosudil
DrugBank: Belumosudil (DB16703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive Placebo for Belumosudil 200 mg daily (increased to 200 mg twice daily in participants receiving concurrent strong CYP3A inducers or PPIs) + maintenance IS for a duration of one year from randomization.
Study: NCT05854498
Drug: Liposomal irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50mg/m2 IV on days 1 and 15
Study: NCT05854498
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5mg/kg IV on days 1 and 15
Study: NCT04812262
Drug: DD01
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The active of DD01 is a synthetic peptide, administered in a 1mL volume for injection.
Study: NCT04895046
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300 mg taken orally (all cycles)
Study: NCT04895046
Drug: Dostarlimab
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg (cycles 1-4) intravenously
Study: NCT04895046
Drug: Dostarlimab
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1000 mg (cycle 5+) intravenously
Study: NCT04765085
Drug: Aripiprazole 5Mg Oral Tablet
Normalized name: Aripiprazole 5mg Oral tablet
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Considering the patients with chronic tic disorder (chronic motor or vocal tic disorder or Tourette's disorder), aripiprazole was selected as a single drug with constant dose during the treatment. In case of extrapyramidal side effects, benhexol was given to reduce the extrapyramidal side effects, and the dosage and duration of medication were recorded
Study: NCT04784442
Drug: 180mg of ETC-1002(bempedoic acid)
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180mg, tablet, once daily, for 12 weeks
Study: NCT04784442
Drug: 120mg of ETC-1002(bempedoic acid)
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120mg, tablet, once daily, for 12 weeks
Study: NCT04784442
Drug: 60mg of ETC-1002(bempedoic acid)
Normalized name: pseudoephedrine hydrochloride 60 MG / triprolidine hydrochloride 2.5 MG [Genac brand of pseudoephedrine/triprolidine]
DrugBank: Triprolidine (DB00427)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60mg, tablet, once daily, for 12 weeks
Study: NCT05969847
Drug: Envafolimab
Normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Envafolimab is administered by subcutaneous injection. The recommended dose is 300 mg per 3 weeks (Q3W) for 6 cycles.
Study: NCT05800327
Drug: Levilimab
Normalized name: Levilimab
DrugBank: Levilimab (DB16387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous or intravenous injection of levilimab with placebo.
Study: NCT05591235
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After the screening period, eligible subjects took the hyperinsulinemic euglycemic clamp test and were then admitted to insulin with metformin for 4 weeks. During this timeframe, all patients were instructed to change the insulin pump infusion site and provide one profile of 7-point self-monitored blood glucose every three days. The insulin doses were titrated every day by physicians to achieve the glycemic goal. Participants who failed to attain the glycemic target in three consecutive times or could not afford the side effects of hypoglycemic medications were excluded from this study. On the last day of week 4, a FreeStyle Libre Pro Sensor (FGM system) was inserted to record the glycemic data for up to 14 days. At the end of week 5, all antidiabetic agents were stopped and the hyperinsulinemic euglycemic clamp test was performed again for remaining subjects.
Study: NCT05591235
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After the screening period, eligible subjects took the hyperinsulinemic euglycemic clamp test and were then admitted to insulin with dapagliflozin (100mg one day) for 4 weeks. During this timeframe, all patients were instructed to change the insulin pump infusion site and provide one profile of 7-point self-monitored blood glucose every three days. The insulin doses were titrated every day by physicians to achieve the glycemic goal. Participants who failed to attain the glycemic target in three consecutive times or could not afford the side effects of hypoglycemic medications were excluded from this study. On the last day of week 4, a FreeStyle Libre Pro Sensor (FGM system) was inserted to record the glycemic data for up to 14 days. At the end of week 5, all antidiabetic agents were stopped and the hyperinsulinemic euglycemic clamp test was performed again for remaining subjects.
Study: NCT05591235
Drug: Fixed-dose combination of metformin and pioglitazone (500mg metformin plus 15mg pioglitazone)
Normalized name: metformin and pioglitazone
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After the screening period, eligible subjects took the hyperinsulinemic euglycemic clamp test and were then admitted to insulin with fixed-dose combination of metformin and pioglitazone (two tablets of 500mg metformin plus 15mg pioglitazone) for 4 weeks. During this timeframe, all patients were instructed to change the insulin pump infusion site and provide one profile of 7-point self-monitored blood glucose every three days. The insulin doses were titrated every day by physicians to achieve the glycemic goal. Participants who failed to attain the glycemic target in three consecutive times or could not afford the side effects of hypoglycemic medications were excluded from this study. On the last day of week 4, a FreeStyle Libre Pro Sensor (FGM system) was inserted to record the glycemic data for up to 14 days. At the end of week 5, all antidiabetic agents were stopped and the hyperinsulinemic euglycemic clamp test was performed again for remaining subjects.
Study: NCT05664568
Drug: Cephalexin
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in intervention group will receive a combination of cephalexin and amoxicillin-clavulanate for the first 2 weeks of TB treatment
Study: NCT05664568
Drug: Amoxicillin-Clavulanate 500 Mg-125 Mg Oral Tablet
Normalized name: amoxicillin-clavulanate 500 mg-125 mg oral tablet
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in the intervention group will receive a combination of cephalexin and amoxicillin-clavulanate for the first 2 weeks of TB treatment
Study: NCT04387240
Drug: Artemisinin / Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: testing the drug capabilities in reducing the shedding and causing the testing for covid 19 to become negative
Study: NCT06086197
Drug: Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anlotinib: 12mg d1\~14 po qd, Rituximab: 375mg/m2 d1, gemcitabine: 1000mg/m2 d1 and d8, oxaliplatin: 130mg/m2 d1;~For subjects ≥75 years of age, appropriate reduction of chemotherapy drugs (not less than 75% of the standard dose, or withdrawal of day 8 gemcitabine) may be decided by the investigator.
Study: NCT04500847
Drug: Emtriva Capsule
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mg daily oral dose
Study: NCT06367712
Drug: Letrozole tablets
Normalized name: Letrozole Tablets
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To determine if the usage of All interventions are effective for simple induction of ovulation in polycystic ovarian syndrome in infertile couples.
Study: NCT06523803
Drug: ZW171
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered per protocol requirements
Study: NCT05070351
Drug: PPI deprescribing
Normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients currently on a proton pump inhibitor (PPI) undergoing transjugular intrahepatic portosystemic shunt (TIPS) creation as part of routine clinical care will be randomized to receive instructions to stop taking their PPI.
Study: NCT06218498
Drug: 5% Minoxidil
Normalized name: MINOXIDIL 5 g in 100 mL TOPICAL LIQUID [ASDTOTIO 5% minoxidil]
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical 5% minoxidil, 1 ml, twice daily
Study: NCT05736549
Drug: Bupivacaine-Liposomal Bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A medication mixture of 40 ml (20 ml LB and 20 ml 0.25% plain bupivacaine) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively.
Study: NCT06140953
Drug: Furosemide or other alternatives , Niaspan or other alternatives
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: conventional treatment will be taken in control group
Study: NCT06140953
Drug: Trimetazidine
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: trimetazidine and conventional therapy
Study: NCT05736549
Drug: Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A medication mixture of 40 ml (40 ml 0.25% plain bupivacaine, 10 mg DEX and 80 mg MPA) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively.
Study: NCT06540872
Drug: [68Ga]Ga-FAPI-46
Normalized name: [68Ga]Ga-FAPI-46
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive the weakly radioactive drug \[68Ga\]Ga-FAPI-46 through their vein and lie in an imaging device (PET/MRI) for 30 minutes. After a break of 30 minutes, they will lie in the imaging device for another 15 minutes.
Study: NCT05679570
Drug: Satralizumab (Genetical Recombination)
Normalized name: satralizumab
DrugBank: Satralizumab (DB15762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Efficacy Evaluation Period:~The study drug will be administered at a dose of 120 mg subcutaneously at initial, 2-week, 4-week, and 4-week intervals thereafter. Efficacy will be assessed after 24 weeks of study drug administration. Subjects who demonstrate efficacy and wish to continue treatment will receive the study drug for 24 weeks and moving to the continuous treatment period. In all other cases, the study will be terminated after 24 weeks of the efficacy evaluation period without the administration of study drug.~Continuation Dosing Period\[1\]:~Subjects who demonstrate efficacy during the efficacy evaluation period and wish to continue will receive continued 28 weeks (52 weeks total) treatment with satralizumab.~Continuation Dosing Period\[2\]:~Subjects completed continuation dosing period\[1\], clinically capable of continued administration, and wish to continue will receive continued treatment with satralizumab until the end of this study period.
Study: NCT05065411
Drug: Enobosarm & Abemaciclib Combo
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive a combo of Enobosarm \& Abemaciclib
Study: NCT05065411
Drug: non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Non-steroidal AI, a steroidal AI (exemestane with or without everolimus), OR fulvestrant
Study: NCT05127746
Drug: Aricept 5mg Tablet
Normalized name: Aricept 5mg Tablet
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet once daily
Study: NCT05127746
Drug: Aricept 10mg Tablet
Normalized name: Aricept 10mg Tablet
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet once daily
Study: NCT05127746
Drug: DA-5207 A
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 patch once weekly
Study: NCT06500026
Drug: BL-B01D1
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT06500026
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT05761717
Drug: Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab I njection
Normalized name: ChulaCov19 mRNA vaccine
DrugBank: ChulaCov19 mRNA vaccine (DB16445)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Injection
Study: NCT05697185
Drug: Evolocumab
Normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients were randomly assigned of the ratio of 1:1 using a computer-generated random number and divided into two treatment groups: the statin alone therapy and the evolocumab plus statin therapy.
Study: NCT05490160
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During the total knee arthroplasty, the patients received a 2-g retrograde injection of tranexamic acid through the drain after closure, with subsequent clamping of the drain for 6 hours.
Study: NCT06520839
Drug: Tadalafil 5mg
Normalized name: TADALAFIL 5MG TAB
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: We will include in the study 90 patients with diabetes and erectile dysfunction. We will use the IIEF-5 questionnaire to confirm the diagnosis of erectile dysfunction. Patients between the ages of 40 and 65 who score 21 points or less on the IIEF-5 scale will be included in the study. Each patient will receive drug tadalafil 5 mg every day for three months.
Study: NCT05054387
Drug: Agalsidase beta
Normalized name: Agalsidase beta
DrugBank: Agalsidase beta (DB00103)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Powder for concentration into a solution Intravenous (IV) infusion
Study: NCT05951959
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Investigational Product
Study: NCT05951959
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Investigator Product
Study: NCT05951959
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Investigator Product
Study: NCT05327803
Drug: Epetraborole
Normalized name: Epetraborole
DrugBank: Epetraborole (DB11744)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg taken orally QD
Study: NCT06547554
Drug: Cefiderocol
Normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Experimental
Study: NCT06578078
Drug: Sodium Zirconium Cyclosilicate
Normalized name: sodium zirconium cyclosilicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Use of sodium zirconium cyclosilicate to optimize RAASi therapy, through up-titration of ACEi, ARB, ARNI or MRA therapy according to clinical guidelines
Study: NCT06250972
Drug: Gemcitabine, Nab-paclitaxel, Irinotecan
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: continuing chemotherapy using the previous regimen until disease progression
Study: NCT00960726
Drug: NOV-002
Normalized name: NOV-002
DrugBank: NOV-002 (DB05393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg delivered daily subcutaneously for up to 12 months.
Study: NCT05657574
Drug: D377
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral, once daily, 8 weeks
Study: NCT05657574
Drug: CKD-331
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, once daily, 8 weeks
Study: NCT06547554
Drug: Xeruborbactam/Cefiderocol
DrugBank: Cefiderocol (DB14879)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A combination of Xeruborbactam and Cefiderocol.
Study: NCT05324761
Drug: Pregabalin 75mg
Normalized name: PREGABALIN 75MG CAP,UD
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Each patient complaining of pain associated with spine surgery who is randomly enrolled this arm of the study and start the specific medication of the arm with the recommended dose and duration for a period of one month, patient will be followed regularly regarding compliance to doses and to register any side effect.
Study: NCT05324761
Drug: Gabapentin 300mg
Normalized name: GABAPENTIN 300MG CAP
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each patient complaining of pain associated with spine surgery who is randomly enrolled this arm of the study and start the specific medication of the arm with the recommended dose and duration for a period of one month, patient will be followed regularly regarding compliance to doses and to register any side effect.
Study: NCT06547554
Drug: Dextrose 5% in water
Normalized name: LVP solution Dextrose 5% in Water intravenous solution
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05983250
Drug: TNX-103
Normalized name: TNX-901
DrugBank: TNX-901 (DB05797)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral levosimendan 1 mg
Study: NCT06286878
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be randomized to use dapagliflozin or placebo in a double-blind way
Study: NCT04893915
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: -Lymphodepleting regimen
Study: NCT04893915
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: -IL-2 will start approximately 2-4 hours after the NK cell infusions.
Study: NCT06650488
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will change from aspirin to clopidogrel (without loading dose)
Study: NCT06650488
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will continue their existing aspirin.
Study: NCT06087627
Drug: Dupilumab SAR231893 (REGN668)
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous injection, standard of care as prescribed by treating physician (no investigational drug provided)
Study: NCT06650332
Drug: cadonilimab
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1:10 mg/kg, iv, Q3W, D1; Cohort 2/3:6 mg/kg, iv, Q2W, D1
Study: NCT06650332
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: loading dose 8 mg/kg, iv, Q3W, D1; maintenance dose 6 mg/kg, iv, Q3W, D1
Study: NCT06650332
Drug: Disitamab Vedotin
Normalized name: Disitamab vedotin
DrugBank: Disitamab vedotin (DB17208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5、2.0、2.5mg/kg，IV，D1，Q2W
Study: NCT05034822
Drug: Ruxolitinib cream
Normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib 1.5% cream applied twice daily.